Nawel Bourayou

Nawel BOURAYOU, MD, MSc, is an experienced leader in immuno-oncology drug development, currently serving as VP and Global Product Head at Incyte since August 2018, where responsibility includes overseeing cross-functional teams and driving integrated product strategies for multiple assets. Prior to Incyte, Nawel held multiple positions at Eli Lilly and Company from June 2007 to August 2018, including VP and Clinical Development Lead, as well as Senior Global Medical Advisor, contributing significantly to the pivotal clinical programs for Abemaciclib in breast cancer and leading various oncology trials in Europe. Nawel's formal education includes a Doctor of Medicine degree in Clinical Oncology from the University of Annaba, Algeria, and multiple post-doctoral qualifications in immuno-oncology, biostatistics, onco-pharmacology, and clinical development.